Product Details
| Alternate Name | Delta variant S1 Protein, Spike glycoprotein subunit 1, Lineage B.1.617.2, SARS-CoV-2 S1 Protein |
|---|---|
| Gene ID | 43740568 |
| Accession # | P0DTC2 |
| Source | HEK 293 cells |
| Appearance | Lyophilized protein |
| Molecular Weight | ~120 kDa (8xHis tag at the C-terminus) |
| Purity by SDS-PAGE | > 95% |
| Formulation | Lyophilized from 0.22 µm filtered PBS (pH 7.4) with 5% trehalose |
| Reconstitution Instructions | Centrifuge the vial prior to opening. Reconstitute in sterile PBS (pH 7.4). Do not vortex. |
| Amino Acid Sequence | Val 16 to Arg 683 (with substitutions at positions T19R, G142D, R158G, K417N, L452R, T478K, D614G and P681R, and deletions of E156 and F157) |
| Handling | Centrifuge the vial prior to opening. |
| Storage Conditions | -20ºC |
| Shipping Conditions | Gel Pack |
| USAGE | For Research Use Only! Not For Use in Humans. |
Details
SARS-CoV-2, the causative virus of COVID-19, uses the viral Spike (S) protein for host cell attachment and entry. The virus uses multiple factors including the human protease Furin, Angiotensin converting enzyme 2 (ACE2), Neuropilin-1 (NRP1) and the transmembrane protease serine 2 (TMPRSS2) for receptor interactions. The S protein has two domains S1 and S2, where S1 facilitates initial binding to the receptor and the S2 domain drives the membrane fusion and eventual entry of the virus. The S glycoprotein serves as an important target for monoclonal antibodies, entry inhibitors, and vaccines. Within the S1 protein, the conserved receptor-binding domain (RBD) binds with a high affinity for ACE2. Of the new emerging strains, SARS-CoV-2 Delta variant (lineage B.1.617.2) has become the dominant strain spreading globally. According to CDC, the Delta variant is more infectious and spreads faster than earlier forms of the virus. The Delta variant S1 domain harbors mutations including (but not limited to): T19R, G142D, E156-, F157-, R158G, K417N, L452R, T478K, D614G and P681R. Out of the several mutations found in the Delta variant, the four spike protein amino acid substitutions (L452R, T478K, D614G, P681R) are of most concern and thought to be the main attributes to the variant’s increased infectivity. Additionally, the Delta variant with the K417N spike mutation has been named “Delta Plus” or "Nepal variant." This K417N mutation is also present in the Beta variant.
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
